- $54 BnWorld market, 2023
- $84.7 BnProjected, 2033
- 4.6%Growth a year (CAGR)
- 9,975Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$22.7 Bn
2.6% a year · 42% of the world -
2
China
$4.3 Bn
6.1% a year · 8% of the world -
3
Canada
$4.3 Bn
4.6% a year · 8% of the world -
4
Japan
$3.4 Bn
5.1% a year · 6.2% of the world -
5
Germany
$2 Bn
2.8% a year · 3.7% of the world -
6
France
$1.5 Bn
3.6% a year · 2.8% of the world -
7
UK
$1.4 Bn
2.6% a year · 2.6% of the world -
8
Brazil
$1.4 Bn
5.6% a year · 2.5% of the world -
9
Italy
$1.3 Bn
4.1% a year · 2.4% of the world -
10
Ecuador
$1.1 Bn
5.2% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
SpainGastrointestinal Drugs by country and region
India
Saudi Arabia
Mexico
Australia
South Africa
UAE
Egypt
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 54,454 papers since 2021
- Safety of proton pump inhibitors in children: A systematic review. British journal of clinical pharmacology, 2026
- The global extent of polypharmacy in neonatal intensive care: A systematic review. British journal of clinical pharmacology, 2026
- Laboratory-to-pilot-scale purification of gastrointestinal-tolerant superoxide dismutase from peanut kernels: Process optimization and in vitro evaluation for oral delivery. Preparative biochemistry & biotechnology, 2026
- Screening for Nutritional Risk in Adults Receiving Obesity Treatment: A Systematic Literature Review of Available Tools and Identification of Conceptual Gaps. Diabetes, obesity & metabolism, 2026
- Sofalcone, a mucoprotective drug, inhibits platelet activation and arterial thrombosis. European journal of pharmacology, 2026
Compare Gastrointestinal Drugs side by side
Key companies in Gastrointestinal Drugs
Sanofi
Bayer AG
Pfizer Inc.
GlaxoSmithKline plc
The Procter & Gamble Company
PV Pharma Healthcare
Roche India
SwisscheM Healthcare Pvt.Ltd
Quick answers
How big is the Gastrointestinal Drugs market?
The world Gastrointestinal Drugs market was worth about $54 Bn in 2023 and is projected to reach $84.7 Bn by 2033, growing 4.6% a year (CAGR).
Which country has the largest Gastrointestinal Drugs market?
The US is the largest of the 24 countries we cover, at $22.7 Bn in 2023. India grows fastest, at 7.6% a year.
How many clinical trials are running in Gastrointestinal Drugs?
ClinicalTrials.gov lists 9,975 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Gastrointestinal Drugs?
PubMed lists about 54,454 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.